All News

Piqray plus Faslodex improved progression-free survival versus Faslodex alone in CDK4/6 inhibitor–pretreated, PIK3CA-mutated advanced breast cancer.

Dr. Roshani Patel answers questions from patients with breast cancer on Keytruda-induced colitis, sugar intake during chemo, and how to stay active.

Joe McDonough sat down for an interview with CURE to share his family’s story and the inspiration behind the B+ Foundation.

Mayra Andujar-Delgado shares how Dr. Faseeh Khaja’s compassionate care and unique bedside manner earned him recognition at the 2025 Blood Cancer Heroes.

Oya Gilbert, diagnosed with multiple myeloma in 2017, advises patients to bring someone to appointments, ask questions and seek second opinions.

Cancer survivor and author Bill Potts was recently honored as a Blood Cancer Hero.

Orserdu plus Verzenio or Afinitor was well tolerated and showed early signs of effectiveness in advanced ER-positive, HER2-negative breast cancer.

CURE spoke with an expert about why a support system is crucial for patients with lung cancer.

BOOG 13-08 shows skipping sentinel lymph node biopsy in patients 50+ with early-stage, hormone receptor–positive, HER2-negative breast cancer is safe.

CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care.

All I can say is thank you Healthwell Foundation for giving our brother life, and for giving our whole family unit life. Because of you, we can keep on keeping on.

Ceralasertib plus Imfinzi failed to improve overall survival versus docetaxel in a phase 3 study of previously treated non-small cell lung cancer.

As kidney cancer survival improves, more patients report cognitive changes affecting memory, fatigue, and overall mental clarity

Christmas is my favorite time of year. Since my child was diagnosed with cancer, however, the only gift I want is one more Christmas with her being here.

Trodelvy elicited fewer side effects that led to dose reduction compared with chemotherapy in previously untreated triple-negative breast cancer.

Jace Yawnick explained why a support system is essential for patients with cancer.

I have been diagnosed with breast cancer for the third time, and I find it interesting how the places where I seek support have changed over time.

Clinical trials give patients with metastatic breast cancer access to new treatments, all while being closely monitored and moving the landscape forward.

Trodelvy led to fewer side effects that required dose reductions or stopping treatment vs chemo among previously untreated triple-negative breast cancer.

At the 2025 SABCS, researchers presented findings with the potential to meaningfully affect breast cancer treatment and patient care.

“Full House” star Dave Coulier, now undergoing treatment for tongue cancer, sat down for an interview with CURE.

Enhertu wins breakthrough therapy designation in some patents with HER2+ early breast cancer who have residual disease following neoadjuvant treatment.

Despite its vital function in many patients’ cancer journeys, palliative care is still the subject of several persistent myths and misconceptions.

From new drug approvals to real-world insights on quality of life, here are the top 10 cancer care stories of 2025 that stood out for their patient impact.

Integrative oncology combines standard treatment with evidence-based complementary therapies to manage symptoms and empower patients.

DESTINY-Breast05 analyses show post neoadjuvant Enhertu improves invasive disease free survival compared with Kadcyla in patients with residual early stage breast cancer.

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments.

Dr. Vikram Gorantla explains to CURE that staying healthy and managing side effects helps patients with brain metastases remain on therapy.